Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor

Between October 2007 and July 2013, 183 Mayo Clinic patients (median age 65 years; 58% males) with high/intermediate risk myelofibrosis (MF) were enrolled in consecutive phase 1/2 JAK2 inhibitor (JAKi) clinical trials with momelotinib (n = 79), ruxolitinib (n = 50), fedratinib (n = 23) and BMS-91154...

Descripción completa

Detalles Bibliográficos
Autores principales: Gangat, Naseema, Begna, Kebede H., Al-Kali, Aref, Hogan, William, Litzow, Mark, Pardanani, Animesh, Tefferi, Ayalew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813003/
https://www.ncbi.nlm.nih.gov/pubmed/36599841
http://dx.doi.org/10.1038/s41408-022-00780-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813003/
https://www.ncbi.nlm.nih.gov/pubmed/36599841
http://dx.doi.org/10.1038/s41408-022-00780-9

Ejemplares similares